Bayer (ETR:BAYN) Third Quarter 2024 Results
Key Financial Results
- Revenue: €9.97b (down 3.6% from 3Q 2023).
- Net loss: €4.18b (loss narrowed by 8.4% from 3Q 2023).
- €4.26 loss per share (improved from €4.65 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Bayer Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) also missed analyst estimates significantly.
Looking ahead, revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany.
Performance of the German Pharmaceuticals industry.
The company's shares are down 16% from a week ago.
Risk Analysis
You should learn about the 1 warning sign we've spotted with Bayer.
Valuation is complex, but we're here to simplify it.
Discover if Bayer might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:BAYN
Bayer
Together its subsidiaries, operates as a life science company worldwide.
Undervalued with moderate growth potential.
